Sarah Grillo / Axios

Acxiom, one of the largest publicly-traded ad tech firms, has sold the majority of its business to Interpublic Group (IPG), one of the largest global advertising holding companies, for $2.3 billion, the companies announced Monday.

Why it matters: It's the latest major ad tech company to go through a big sale as the data-driven advertising market continues to be squeezed by business pressure from tech giants like Google and Facebook and regulatory pressure around data privacy.

What's at stake: The deal allows Acxiom to offload its Marketing Solutions division, which took a hit when Facebook began cracking down on third-party data brokers after the Cambridge Analytica data scandal. It gives IPG access to billions of consumer data sets to its grow its data-driven, ad-buying business.

  • Analysts note that the acquisition reaffirms IPG's commitment to remaining a publicly-traded company.
  • Arun Kumar, IPG’s first global chief data and marketing technology officer, will oversee the acquisition.
  • But, but, but: Senior advertising analyst Brian Weiner warns in a Wall Street Journal interview that the acquisition could pose some risk to IPG, given all of the public and regulatory attention around data privacy.

Acxiom will remain a publicly-traded company, and will retain LiveRamp, a platform that helps mine, identify and move data that it acquired in 2014. LiveRamp has since become its fastest-growing division.

  • Acxiom says it will rename its company "LiveRamp" and will begin trading its common stock under the new ticker symbol “RAMP."
  • Acxiom says it's offloading its marketing solutions business, which accounts for the majority of its revenue, to help drive greater financial flexibility for further deals down the line.
  • The transaction is expected to close in the third quarter of 2018, pending regulatory approval.

Between the lines: Acxiom had been looking to sell off its marketing solutions business for some time. Several agencies were interested in the acquisition, according to previous reports.

  • Acxiom says it finally sold to IPG because it offered an all-cash transaction and because of the strong working relationship the two companies have already created.
  • Acxiom and IPG formed a global partnership late last year to strengthen IPG’s data and analytics capabilities for its media buying and digital agencies, Initiative and UM.

Go deeper

Updated 4 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Global: Total confirmed cases as of 9 p.m. ET: 20,755,406 — Total deaths: 752,225— Total recoveries: 12,917,934Map.
  2. U.S.: Total confirmed cases as of 9 p.m. ET: 5,246,760 — Total deaths: 167,052 — Total recoveries: 1,774,648 — Total tests: 64,831,306Map.
  3. Politics: House Democrats to investigate scientist leading "Operation Warp Speed" vaccine projectMcConnell announces Senate will not hold votes until Sept. 8 unless stimulus deal is reached.
  4. 2020: Biden calls for 3-month national mask mandateBiden and Harris to receive coronavirus briefings 4 times a week.
  5. States: Georgia Gov. Brian Kemp to drop lawsuit over Atlanta's mask mandate.
  6. Business: Why the CARES Act makes 2020 the best year for companies to lose money.
  7. Public health: Fauci's guidance on pre-vaccine coronavirus treatments Cases are falling, but don't get too comfortable.

Trump says he intends to give RNC speech on White House lawn

President Trump speaking to reporters on South Lawn in July. Photo: Jabin Botsford/The Washington Post via Getty Images

President Trump told the New York Post on Thursday that he plans to deliver his Republican National Convention speech from the White House lawn, despite bipartisan criticism of the optics and legality of the location.

Why it matters: Previous presidents avoided blurring staged campaign-style events — like party conventions — with official business of governing on the White House premises, per Politico.

Fauci's guidance on pre-vaccine coronavirus treatments

Illustration: Aïda Amer/Axios

Antibody drugs and various medicine cocktails against the coronavirus are progressing and may provide some relief before vaccines.

The big picture: Everyone wants to know how and when they can return to "normal" life, as vaccines are not expected to be ready for most Americans for at least a year. Two therapies are known to be helpful, and more could be announced by late September, NIAID Director Anthony Fauci tells Axios.